Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2016-11-10 Proxy Solicitation & In…
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2016-11-10 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, specifically reporting the results of operations and financial condition for the three and nine months ended September 30, 2016. It references a press release attached as Exhibit 99.1 announcing these results. The document is relatively short (3807 characters) and primarily serves to announce the earnings results rather than providing a full detailed financial report. The language indicates it is furnishing information under Item 2.02 of Form 8-K, which is typically used for earnings releases or similar announcements. Therefore, this document fits the definition of an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2016-11-08 English
FORM 10-Q
Interim / Quarterly Report Q3 2016
2016-11-08 English
Director's Dealing 2016
Director's Dealing
2016-10-25 English
Director's Dealing 2016
Director's Dealing
2016-10-25 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of up to 2,000,000 shares of common stock by selling stockholders. It includes detailed information about the company, the securities offered, risk factors, use of proceeds, selling stockholders, and plan of distribution. The document is not an annual report, earnings release, or management discussion, but a registration prospectus for secondary share sales. This fits the definition of a Capital/Financing Update (CAP) as it relates to securities offering and capital structure changes. The document length is substantial (15,000 characters) and contains detailed offering information, not just an announcement or a brief summary, confirming it is a full prospectus filing under Rule 424(b)(3).
2016-10-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.